Abstract
Objective This study investigated whether digital PCR (dPCR)-based circulating tumor DNA (ctDNA) monitoringcan allow longer intervals between computed tomography (CT) scans during postoperative surveillance of colorectal cancer (CRC).
Design The longitudinal dynamics of ctDNA for 52 patients with CRC as measured by dPCR using probes targeting 87 individual tumor-specific mutations (1-5 per patient) were compared with results from conventional (i.e., clinical) surveillance using serum tumor markers and CT. A total of 382 CT procedures were carried out for the patient cohort (3.3/year per patient) and the median lead time from ctDNA relapse to clinical relapse was 182 days (range 0-376 days). If the CT interval was annual, potential delays in detection of clinical relapse would have occurred for 7 of the 10 patients who experienced clinical relapse (9 of 13 events), with a median delay of 164 days (range, 0-267 days). If annual CT surveillance was performed together with ctDNA monitoring, 218 (57.1%) CTs would not have been needed to detect the first clinical relapse. Nonetheless, ctDNA monitoring would still have provided a lead time of 339 days for detection of clinical relapse (range, 42-533 days).
Conclusion Our findings suggest that the ctDNA monitoring as part of post-operative surveillance and clinical relapse detection for patients with CRC could allow the CT interval to be lengthened.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
UMIN Clinical Trial Registry number, UMIN000045114
Funding Statement
This work was supported by a Grant-in-Aid for Scientific Research KAKENHI [16K19951, 16K19952, 16H06279, 17K10605, 19K09224, 20K09064, 20K08966, and 21K07223], Keiryokai Collaborative Research Grant [#136 and #145], and Iwate Prefectural Research Grants [H30, R2, and R3]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Iwate Medical University (IRB #HGH28-15 and #MH2021-073).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Title and content with unclear descriptions have been revised to make the research purpose, results, and discussion clear. Authors have removed unessential figures in previous version (i.e., Figure 2B, 2C, 5A, 5B, Supplementary Figure 2, 3, 6, 7, and 9).
Data Availability
All data produced in the present work are contained in the manuscript.
